PBM logo

PSYENCE BIOMEDICAL LTD

PBMNASDAQ
๐Ÿ† #4730 by market capUS Equity
$2.87โ€”
Last available close ยท quote unavailable
๐Ÿ””
Track PBM
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ–ผ 8.6%
14dโ–ผ 3.0%
30dโ–ผ 32.2%
ytdโ–ผ 38.2%
1yโ–ผ 70.0%
๐ŸฆMarket Cap
$11M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
โ€”
52-Week Range
$1.92 โ€“ $89.44
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
3.8M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-98.35
Dividend Yield
โ€”
PBM logo

PSYENCE BIOMEDICAL LTD

PBM
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.